Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31461
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVermersch, P.-
dc.contributor.authorEralinna, J.-
dc.contributor.authorNicholas, R.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorSiva, A.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWiendl, H.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorWei, W.-
dc.contributor.authorComi, G.-
dc.date.accessioned2020-07-10T12:22:29Z-
dc.date.available2020-07-10T12:22:29Z-
dc.date.issued2020-
dc.date.submitted2020-07-08T10:47:46Z-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 26 (1_SUPPL) , p. 32 -32-
dc.identifier.urihttp://hdl.handle.net/1942/31461-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.rights2020 by SAGE Publications.-
dc.titleEfficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateFEB 27-29, 2020-
local.bibliographicCitation.conferencenameAmericas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-
local.bibliographicCitation.conferencename(ACTRIMS) Forum-
local.bibliographicCitation.conferenceplaceWest Palm Beach, FL-
dc.identifier.epage32-
dc.identifier.issue1_SUPPL-
dc.identifier.spage32-
dc.identifier.volume26-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isiWOS:000532412600068-
dc.identifier.eissn1477-0970-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Vermersch, P.] Univ Lille, Lille, France.-
local.description.affiliation[Eralinna, J.] NEO Res, Turku, Finland.-
local.description.affiliation[Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England.-
local.description.affiliation[Nicholas, R.] Imperial Coll, London, England.-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Siva, A.] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey.-
local.description.affiliation[Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium.-
local.description.affiliation[Van Wijmeersch, B.] Rehabil & MS Ctr, Overpelt, Belgium.-
local.description.affiliation[Wiendl, H.] Univ Munster, Munster, Germany.-
local.description.affiliation[Buffels, R.; Wei, W.] F Hoffmann Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
item.fullcitationVermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W. & Comi, G. (2020) Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results). In: MULTIPLE SCLEROSIS JOURNAL, 26 (1_SUPPL) , p. 32 -32.-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.contributorVermersch, P.-
item.contributorEralinna, J.-
item.contributorNicholas, R.-
item.contributorOreja-Guevara, C.-
item.contributorSiva, A.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWiendl, H.-
item.contributorBuffels, R.-
item.contributorWei, W.-
item.contributorComi, G.-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
vermersch_2020.pdf
  Restricted Access		Published version107.04 kBAdobe PDFView/Open    Request a copy
Show simple item record

Page view(s)

20
checked on Sep 7, 2022

Download(s)

36
checked on Sep 7, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.